Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1793 results
February 2016
-
5 tips for making smart decisions on research projects
Make smart decisions about your research projects.
-
Media ReleaseFDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NET Approval helps fulfill unmet need as…
-
In The NewsNovartis Access perspectives: Tailoring tactics to tackle chronic disease in low-income countriesHealthcare expert Dr. Jonathan D. Quick discusses solutions to address the rapid rise of chronic illnesses in the developing world
-
Media ReleaseNovartis shareholders approve all resolutions proposed by Board of DirectorsShareholders approve 19th consecutive dividend increase to CHF 2.70 (+4%) per share for 2015 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well as…
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administrationLes actionnaires approuvent la 19e hausse consécutive du dividende, à CHF 2,70 par action (+4%) au titre de l'exercice 2015. Le Dr Joerg Reinhardt est confirmé par les actionnaires dans ses fonctions…
-
Media ReleaseNovartis Aktionäre genehmigen alle Anträge des VerwaltungsratsAktionäre genehmigen für 2015 die 19. Dividendenerhöhung in Folge auf CHF 2,70 pro Aktie (+4%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats ebenso wie alle weiteren Mitglieder des…
-
CRISPR genome editing fuels cancer drug discovery
Genome editing advances drug discovery in biomedical research.
-
Media ReleaseNovartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)PKC412 (midostaurin) significantly improved overall survival of adult patients eligible to receive standard induction and consolidation chemotherapy AML has the lowest survival rate of all adult…
-
Media ReleaseAlcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma The goal of MIGS is to reduce or…
-
Tailoring tactics to tackle chronic disease in low-income countries
Healthcare expert Dr. Jonathan D. Quick discusses solutions to address the rapid rise of chronic illnesses in the developing world.
-
In The NewsJoe Jimenez on how to improve healthcareIn an op ed with Foreign Affairs, Joe Jimenez explains why outcomes, innovation and collaboration are the keys to improving healthcare worldwide.
Pagination
- ‹ Previous page
- 1
- …
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- …
- 150
- › Next page